10-Q: Sharps Technology Reports Net Income of $1.9 Million in Q1 2025 Following Equity Offering and Debt Repayment

Sharps Technology reports a net income of $1.9 million for the quarter ended March 31, 2025, driven by a fair market value adjustment on warrants and the closing of a $20 million equity offering.

Summary

• Sharps Technology, Inc., a pre-revenue medical device and pharmaceutical packaging company, reported its Q1 2025 financial results.
• The company generated no revenue during the quarter, consistent with the same period in 2024.
• Net income for Q1 2025 was $1.9 million, a significant improvement compared to a net loss of $982,386 in Q1 2024.
• This turnaround was primarily due to a $4.6 million fair market value (FMV) adjustment on warrants.
• Operating expenses totaled $2.0 million, including $82,016 in research and development and $1.9 million in general and administrative costs.
• The company completed an equity offering in January 2025, raising gross proceeds of $20.0 million and net proceeds of $18.2 million.
• Approximately $4.2 million of the offering proceeds were used to repay outstanding debt.
• As of March 31, 2025, Sharps Technology had a cash balance of $11.9 million and working capital of $5.6 million.
• The company is pursuing commercialization of its safety syringe products and expects to transition to revenue generation in the second half of 2025.
• Sharps Technology is facing legal proceedings, including lawsuits from Barry Berler and Plastomold Industries Ltd., which the company intends to defend vigorously.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. The company achieved net income and strengthened its balance sheet through an equity offering. However, it is still pre-revenue and faces legal challenges and delays in product commercialization.

Positives

• The company achieved net income of $1.9 million in Q1 2025, a significant improvement from the net loss in Q1 2024.
• The successful equity offering in January 2025 strengthened the company's balance sheet, providing $18.2 million in net proceeds.
• The company repaid its outstanding debt, resulting in a debt-free balance sheet.
• The cash position significantly improved to $11.9 million as of March 31, 2025.
• The company received an initial purchase order under a supply agreement with Stericare Solutions, signaling progress towards revenue generation.
• The company's stockholders equity is $10,135,328 and meets the continued listing requirement of $2,500,000.

Negatives

• The company has not generated any revenue to date.
• The company is involved in ongoing legal proceedings, which could result in significant expenses and potential liabilities.
• The company has a history of net losses and negative cash flow from operations.
• The company is not eligible for any compliance period due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one.
• The company was notified by the Staff of The Nasdaq that it was not in compliance with the $2,500,000 stockholders equity requirement for continued listing (the Rule ) on The Nasdaq Capital Market.

Risks

• The company's ability to continue as a going concern is dependent on its ability to commercialize its products or raise sufficient financing.
• Delays in the commercialization of the Sharps Provensa product line continue.
• The company is subject to risks associated with legal proceedings, including potential adverse outcomes and associated costs.
• The company's success depends on its ability to secure manufacturing capacity for its next-generation polymer-based prefillable syringes.
• The company's common stock and warrants will remain listed on Nasdaq under its existing symbols, STSS and STSSW while it awaits the hearing and Panel decision.
• The company is not eligible for any compliance period due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one.

Future Outlook

The company expects to transition to revenue generation in the second half of 2025 and is committed to driving revenue growth from both the Securegard and Sologard projects in 2025, as well as securing manufacturing capacity for the Companys next generation polymer-based prefillable syringes.

Management Comments

• With the recent financing secured, the Company believes that it is positioned to advance its growth strategy by utilizing its working capital to support essential operating expenses.
• Production is currently on track, with the Company preparing for a transition to revenue in the second half of 2025, subject to the successful execution of its plans.

Industry Context

The medical device and pharmaceutical packaging industry is highly competitive, with companies constantly innovating to improve safety and efficiency. Sharps Technology is focused on commercializing its safety syringe products to address the growing demand for safer injection practices and prefillable syringes.

Comparison to Industry Standards

• It is difficult to compare Sharps Technology to industry standards due to its pre-revenue status.
• Comparable companies in the medical device space, such as Becton Dickinson and Medtronic, have established revenue streams and diverse product portfolios.
• However, Sharps Technology's focus on safety syringe technology aligns with the industry's emphasis on patient safety and infection control.
• The company's ability to secure manufacturing capacity and commercialize its products will be critical to its success in the long term.

Legal Proceedings

• Barry Berler, a co-founder and former Chief Technology Officer of the Company, commenced a lawsuit in the United States District Court for the Eastern District of New York, Barry Berler v. Sharps Technology, Inc. and Alan Blackman, Case No. 2:24-cv-04787.
• Berler filed a demand for arbitration and statement of claim under the commercial arbitration rules of the American Arbitration Association (AAA) asserting claims for payment of $500,000 plus interest, under the Companys royalty agreement with Berler, as amended, rescission thereof and reversion to Berler of the intellectual property rights subject thereto.
• Plastomold commenced a lawsuit against the Company in the United States District Court for the Eastern District of New York, Plastomold Industries Ltd v. Sharps Technology, Inc., Case No. 2:24-CV-02580, asserting claims for damages in the amount of $1.762 million.

Related Party Transactions

• As of March 31, 2025 and December 31, 2024, accounts payable and accrued liabilities include $ 22,000 and $ 99,500 , respectively, payable to officers and directors of the Company.

Stakeholder Impact

• The company's financial performance and future prospects will impact shareholders, employees, customers, and suppliers.
• The successful commercialization of its products could create value for shareholders and provide employment opportunities.
• The company's ability to meet its obligations to suppliers and customers will be critical to maintaining its reputation and relationships.

Next Steps

• The company intends to finance its future development and commercialization activities and its working capital needs with the recent offering proceeds and further with the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements.
• The company is preparing for a transition to revenue in the second half of 2025, subject to the successful execution of its plans.

Key Dates

Keywords

Sharps Technology, financial results, equity offering, net income, warrants, debt repayment, Stericare, legal proceedings, revenue, syringe products